{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T08:03:59Z","timestamp":1784102639305,"version":"3.55.0"},"reference-count":9,"publisher":"American Association for Cancer Research (AACR)","issue":"14","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7,15]]},"abstract":"<jats:p>Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer death in the United States, driven by its aggressive biology and high metastatic incidence at diagnosis. With a 5-year survival rate of just 8%, PDAC remains one of the most lethal cancers. Mutant KRAS, present in more than 90% of cases, serves as a key driver of tumorigenesis and metabolic reprogramming. In this issue of Cancer Research, Thakur and colleagues uncover a novel metabolic adaptation that PDAC cells use to survive therapeutic stress. Their integrated metabolomic and lipidomic analyses show that ERK inhibition\u2014targeting a key KRAS pathway effector\u2014not only disrupts glycolysis and glutamine metabolism but also triggers a compensatory increase in fatty acid oxidation (FAO). This shift occurs through lipophagy, a lysosome-mediated lipid degradation process, rather than cytosolic lipolysis. Mechanistically, ERK inhibition promotes the nuclear translocation of TFEB, which drives the upregulation of FAO and lipophagy genes. This metabolic reprogramming enables PDAC cells to survive KRAS pathway blockade. Importantly, cotargeting FAO alongside ERK or KRAS inhibitors elicits a potent synergistic antitumor effect in vivo. This dual-target strategy holds promise for overcoming PDAC resistance to KRAS-targeted therapies, laying the groundwork for novel combination treatments.<\/jats:p>\n                  <jats:p>See related article by Thakur et al., p. 3519<\/jats:p>","DOI":"10.1158\/0008-5472.can-25-1877","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T07:06:56Z","timestamp":1784099216000},"page":"3374-3376","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["KRAS on Empty: Lipid Oxidation Blockade Reveals a Metabolic Achilles\u2019 Heel in Pancreatic Cancer"],"prefix":"10.1158","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-5654-4863","authenticated-orcid":false,"given":"Deborah de la Caridad","family":"Delgado Herrera","sequence":"first","affiliation":[{"name":"1University of Maryland School of Medicine, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8651-9154","authenticated-orcid":false,"given":"Christina M.","family":"Ferrer","sequence":"additional","affiliation":[{"name":"1University of Maryland School of Medicine, Baltimore, Maryland."},{"name":"2The University of Maryland Marlene and Stuart Greenebaum Comprehensive Cancer Center, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"2026071503065245700_bib1","first-page":"10","article-title":"Cancer statistics","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"2026071503065245700_bib2","doi-asserted-by":"crossref","first-page":"154603","DOI":"10.1016\/j.prp.2023.154603","article-title":"The KRAS signaling pathway\u2019s impact on the characteristics of pancreatic cancer cells","volume":"248","author":"Chen","year":"2023","journal-title":"Pathol Res Pract"},{"key":"2026071503065245700_bib3","doi-asserted-by":"crossref","first-page":"4932","DOI":"10.1158\/0008-5472.CAN-20-1255","article-title":"KRAS controls pancreatic cancer cell lipid metabolism and invasive potential through the lipase HSL","volume":"80","author":"Rozeveld","year":"2020","journal-title":"Cancer Res"},{"key":"2026071503065245700_bib4","first-page":"3519","article-title":"Lipophagy-dependent fatty acid oxidation is a metabolic vulnerability for KRAS signaling inhibition in pancreatic cancer","volume":"86","author":"Thakur","year":"2026","journal-title":"Cancer Res"},{"key":"2026071503065245700_bib5","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41420-024-01933-4","article-title":"Potential role of lipophagy impairment for anticancer effects of glycolysis-suppressed pancreatic ductal adenocarcinoma cells","volume":"10","author":"Zhang","year":"2024","journal-title":"Cell Death Discov"},{"key":"2026071503065245700_bib6","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/nature13611","article-title":"Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function","volume":"514","author":"Viale","year":"2014","journal-title":"Nature"},{"key":"2026071503065245700_bib7","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1038\/s41591-022-02007-7","article-title":"Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor","volume":"28","author":"Hallin","year":"2022","journal-title":"Nat Med"},{"key":"2026071503065245700_bib8","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41573-020-0068-6","article-title":"RAS-targeted therapies: is the undruggable drugged?","volume":"19","author":"Moore","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"2026071503065245700_bib9","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","article-title":"The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth","volume":"41","author":"de Visser","year":"2023","journal-title":"Cancer Cell"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/86\/14\/3374\/3810949\/can-25-1877.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/86\/14\/3374\/3810949\/can-25-1877.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T07:06:58Z","timestamp":1784099218000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/86\/14\/3374\/786560\/KRAS-on-Empty-Lipid-Oxidation-Blockade-Reveals-a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":9,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2026,7,15]]},"published-print":{"date-parts":[[2026,7,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-25-1877","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]}}}